Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer

References

• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011 Aug;12(8):735–742.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380–8. doi: 10.1056/NEJMoa0909530
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA-Approved Drugs [cited 2023 Oct 15]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
   Google Scholar
• Sundaresan TK, Sequist LV, Heymach JV, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res. 2016 Mar 1;22(5):1103–1110. doi: 10.1158/1078-0432.CCR-15-1031
   PubMed Web of Science ®Google Scholar
• Yang J-H, Ahn M-J, Kim D-W, et al. Osimertinib in pretreated T790M-Positive advanced non–small-Cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–1296. doi: 10.1200/JCO.2016.70.3223
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113–125. doi: 10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41–50. doi: 10.1056/NEJMoa1913662
   PubMed Web of Science ®Google Scholar
• Ewer MS, Tekumalla SH, Walding A, et al. Cardiac Safety of osimertinib: a Review of data. J Clin Oncol. 2021 Feb 1;39(4):328–337. doi: 10.1200/JCO.20.01171
   PubMed Web of Science ®Google Scholar
• Kunimasa K, Oka T, Hara S. et al. Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer. 2021 Mar;153:186–192.
   PubMed Web of Science ®Google Scholar
• Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):868–877. doi: 10.1161/CIRCEP.111.962019
   PubMed Web of Science ®Google Scholar
• Mezquita L, Varga A, Planchard D. Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Expert Opin Drug Saf. 2018 Dec;17(12):1239–1248. doi: 10.1080/14740338.2018.1549222
   PubMed Web of Science ®Google Scholar
• Kloth JS, Pagani A, Verboom MC, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015 Mar 17;112(6):1011–1016. doi: 10.1038/bjc.2015.82
   PubMed Web of Science ®Google Scholar
• Dong Q, XX F, LL D, et al. Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate. Biol Pharm Bull. 2013;36(2):268–75. doi: 10.1248/bpb.b12-00778
   PubMed Web of Science ®Google Scholar
• Gibbs C, Thalamus J, Kristoffersen DT, et al. QT prolongation predicts short-term mortality independent of comorbidity. EP Europace. 2019 Aug 1;21(8):1254–1260. doi: 10.1093/europace/euz058
   PubMed Web of Science ®Google Scholar
• Kim P, Masha L, Olson A, et al. QT prolongation in cancer patients. Front Cardiovasc Med. 2021;8:613625. doi: 10.3389/fcvm.2021.613625
   PubMed Web of Science ®Google Scholar
• Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006 Jan 17;47(2):362–7. doi: 10.1016/j.jacc.2005.08.067
   PubMed Web of Science ®Google Scholar
• Zhang Y, Post WS, Dalal D, et al. QT-interval duration and mortality rate: results from the third National Health and nutrition examination survey. Arch Intern Med. 2011 Oct 24;171(19):1727–33. doi: 10.1001/archinternmed.2011.433
   PubMed Web of Science ®Google Scholar
• Zareba W. Drug induced QT prolongation. Cardiol J. 2007;14(6):523–533.
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services Food and Drug Administration. E14 Clinical Evaluation Of QT/QTc Interval Prolongation And Proarrhythmic Potential For Non-Antiarrhythmic Drugs. FDA Guidance Documents. 2012 [cited 2023 Dec 15]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e14-clinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-0.
   Google Scholar
• Rossi M, Marzi F, Natale M, et al. Drug-associated QTc prolongation in geriatric hospitalized patients: a cross-sectional study in internal Medicine. Drugs Real World Outcomes. 2021 Sep;8(3):325–335.
   PubMedGoogle Scholar
• Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. P T. 2017 Jul;42(7):473–477. doi: 10.1016/j.eupc.2005.05.010
   PubMedGoogle Scholar
• Bardaro F, Stirpe E. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma. J Oncol Pharm Pract. 2022 Jun;28(4):989–994. doi: 10.1177/10781552211073823
   PubMed Web of Science ®Google Scholar
• Bian S, Tang X, Lei W. A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin. BMC Pulm Med. 2020 Jun 24;20(1):181. doi: 10.1186/s12890-020-01217-4
   PubMed Web of Science ®Google Scholar
• Medepalli L C, Jolly P C, Vallakati A, et al. Osimertinib- cardiac dysfunction with prolonged QTc interval: a case report. Cardiol Cardiovasc Med. 2022;6(03). doi: 10.26502/fccm.92920263
   Google Scholar
• Kondo M, Kisanuki M, Kokawa Y, et al. Case report: QT prolongation and abortive sudden death observed in an 85-year-old female patient with advanced lung cancer treated with tyrosine kinase inhibitor osimertinib. Front Cardiovasc Med. 2021;8:655808. doi: 10.3389/fcvm.2021.655808
   PubMed Web of Science ®Google Scholar
• Schiefer M, Hendriks LEL, Dinh T. et al. Current perspective: osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer. 2018 Mar;91:92–98.
   PubMed Web of Science ®Google Scholar
• Manini AF, Stimmel B, Vlahov D. Racial susceptibility for QT prolongation in acute drug overdoses. J Electrocardiol. 2014 Mar;47(2):244–50. doi: 10.1016/j.jelectrocard.2013.12.002
   PubMed Web of Science ®Google Scholar
• Shah RR. Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol. 2013 Feb;75(2):347–358. doi: 10.1111/j.1365-2125.2012.04415.x
   PubMed Web of Science ®Google Scholar
• Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-induced cardiotoxicity: a retrospective Review of the FDA adverse events reporting System (FAERS). JACC Cardio Oncol. 2019 Dec;1(2):172–178.
   PubMedGoogle Scholar
• Medicare.gov [2023 Jan 31]. Available from: https://www.medicare.gov/basics/get-started-with-medicare
   Google Scholar
• SEER-Medicare: brief Description of the SEER-Medicare database [2023 Jan 31]. Available from: https://healthcaredelivery.cancer.gov/seermedicare/overview/
   Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results Program [2023 Jan 31]. Available from: https://seer.cancer.gov/registries/cancer_registry/index.html
   Google Scholar
• NCI. SEER program. ICD-O-3 Coding Materials [cited 2023 Oct 15]. Available from: https://seer.cancer.gov/icd-o-3/
   Google Scholar
• Lee SB, Oh JH, Park JH, et al. Differences in youngest-old, middle-old, and oldest-old patients who visit the emergency department. Clin Exp Emerg Med. 2018 Dec;5(4):249–255.
   PubMed Web of Science ®Google Scholar
• Quinones ME, Joseph JK, Dowell S, et al. Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study with 19-Year Follow-up. Arthritis Care Res (Hoboken). 2023;75(7):1571–1579. doi: 10.1002/acr.25005
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Division of Cancer Control & Population Sciences. Comorbidity SAS Macro (2021 version) [cited 2023 Apr 7]. Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/macro-2021.html
   Google Scholar
• MR S, D-R P, JL W, et al. Comorbidity technical report. The Impact of different SEER-Medicare Claims-based Comorbidity Indexes on predicting non-cancer mortality for cancer patients.
   Google Scholar
• Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022 Jan;15(1):14–20.
   PubMed Web of Science ®Google Scholar
• Porta-Sanchez A, Gilbert C, Spears D, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic Review. J Am Heart Assoc. 2017 Dec 7;6(12). doi: 10.1161/JAHA.117.007724
   Web of Science ®Google Scholar
• Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006 Jan;259(1):59–69. doi: 10.1111/j.1365-2796.2005.01589.x
   PubMed Web of Science ®Google Scholar
• Diez-Escute N, Arbelo E, Martinez-Barrios E, et al. Sex differences in long QT syndrome. Front Cardiovasc Med. 2023;10:1164028. doi: 10.3389/fcvm.2023.1164028
   PubMed Web of Science ®Google Scholar
• Niemeijer MN, van den Berg ME, Eijgelsheim M, et al. Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Saf. 2015 Oct;38(10):855–867.
   PubMed Web of Science ®Google Scholar
• Lee CS, Ahmed I, Miao E, et al. A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: a multi-center, retrospective study. J Oncol Pharm Pract. 2021 Jun 13;28(5):1140–1151. doi: 10.1177/10781552211020798
   PubMed Web of Science ®Google Scholar
• Peled N, Kian W, Inbar E, et al. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neurooncol Adv. 2022 Jan;4(1):vdab188.
   PubMedGoogle Scholar
• Yamamoto G, Asahina H, Honjo O, et al. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002). Sci Rep. 2021 Nov 30;11(1):23140. doi: 10.1038/s41598-021-02561-z
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER-Medicare. Measures that are limited or not available in the data [cited 2023 Apr 26]. Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html#2
   Google Scholar
• Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000 Sep 5;102(10):1178–1185. doi: 10.1161/01.CIR.102.10.1178
   PubMed Web of Science ®Google Scholar